ADAGIO misses a beat?

The Lancet Neurology

Volumn 8, Issue 12, 2009, Pages 1081-1082

  Kieburtz, Karl ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LEVODOPA; RASAGILINE;

CLINICAL PRACTICE; DISABILITY; FOOD AND DRUG ADMINISTRATION; HUMAN; LETTER; MONOTHERAPY; PARKINSON DISEASE; PRIORITY JOURNAL; RATING SCALE; TREATMENT OUTCOME;

ANTIPARKINSON AGENTS; DISEASE PROGRESSION; HUMANS; LEVODOPA; MONOAMINE OXIDASE INHIBITORS; PARKINSON DISEASE; RESEARCH DESIGN; THIAZOLIDINEDIONES; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 71949112811     PISSN: 14744422     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1474-4422(09)70297-2     Document Type: Letter

References (6)

1. Olanow C.W., Rascol O., Hauser R., et al., for the ADAGIO Study Investigators. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med 361 (2009) 1268-1278
2. Parkinson Study Group. A controlled trial of rasagiline in early Parkinson disease. The TEMPO Study. Arch Neurol 59 (2002) 1937-1943
3. Parkinson Study Group. Randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations. The PRESTO Study. Arch Neurol 62 (2005) 241-248
4. Rascol O., Brooks D.J., Melamed E., et al. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet 365 (2005) 947-954
5. Leber P. Observations and suggestions on anti-dementia drug developments. Alzheimer Dis Assoc Disord 10 suppl 1 (1996) 31-35
6. D'Agostino R.B. The delayed-start study design. N Engl J Med 361 (2009) 1304-1306